Novo Nordisk, the Danish pharmaceutical giant, saw its shares fall by 7% despite setting a $23 billion sales target for its weight-loss drug.
Novo Nordisk's share price fell by as much as 7% on Monday after the company unveiled new growth ambitions aimed at reinvigorating its position in the booming obesity drug market. The company plans to launch more than five drugs with "multiple blockbuster" potential by 2030 and expects to achieve over DKK 150 billion (approximately $23 billion) in R&D pipeline sales by 2035. Additionally, Novo Nordisk anticipates revenue growth from 2026 to 2030 to be in line with industry peers.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
SK Hynix fell 6.02% from its previous close, currently trading at ₩1,312,000.
-
2
Samsung Electronics fell 5.85% from its previous close, currently trading at ₩205,250.
-
3
SK Hynix fell 9.31% from its previous close, currently trading at ₩1,266,000.
-
4
SK Hynix fell 7.81% from its previous close, currently trading at ₩1,287,000.
-
5
NVIDIA fell 3.32% from its previous close, currently trading at $199.820
-
6
South Korea's KOSPI index fell 4% from the previous close, currently trading at 5,456.25
-
7
Phoenix (PHB) Project Analysis: Technical Vision, Ecosystem Matrix, and Current Development Status
-
8
What Are Cryptocurrency Exchanges: How to Choose Between CEX and DEX
-
9
Bank of Japan September Meeting Minutes: Voted 7-2 to Raise Rates to Around 1.25% at the Time
-
10
What is WCFX (Wrapped Conflux)? 2026 Ecological Progress and Outlook Analysis
Markets Today
Recommended Reading




